Trifluridine/tipiracil and survival in mismatch repair-deficient metastatic colorectal cancer
Therapeutic Advances in Medical Oncology · 2026-06 · 18
DOI: 10.1177/17588359261458757 ↗Kurz gefasst
Fachartikel in der Zeitschrift Therapeutic Advances in Medical Oncology, online erschienen am 16.06.2026. Verfasst von Pei-Hung Chang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology-Oncology, Department of Internal Medicine, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Taiwan Association of Cancer Research.
Abstract (Originalsprache)
Background
While trifluridine/tipiracil (FTD/TPI) is approved for refractory metastatic colorectal cancer (mCRC), its clinical benefit may vary based on molecular and clinical characteristics.
Objectives
To identify clinical and molecular factors associated with overall survival (OS) in patients with refractory mCRC treated with FTD/TPI.
Design
Retrospective, multicenter study.
Methods
A retrospective multicenter cohort study of 591 mCRC patients treated with FTD/TPI was conducted. Cox regression was used to identify independent prognostic factors for overall survival (OS).
Results
Median OS was 7.8 months in the overall cohort. Patients with deficient mismatch repair (dMMR) had significantly longer OS than those with proficient MMR ( p = 0.001). Body mass index (BMI) (hazard ratio (HR) = 0.96), neutrophil-to-lymphocyte ratio ⩾3 (HR = 1.94), and dMMR status (HR=0.29) were independent predictors of OS (all p < 0.001).
Conclusion
In this retrospective multicenter cohort, MMR status, BMI, and neutrophil-to-lymphocyte ratio (NLR) were identified as factors independently associated with OS among patients with refractory mCRC treated with FTD/TPI. These findings support the integration of molecular and clinical factors for prognostic stratification in later-line treatment settings
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Hematology-Oncology, Department of Internal Medicine, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan.
- College of Medicine, Chang Gung University, Taoyuan, Taiwan.
- Division of Hematology-Oncology, Department of Internal Medicine, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan.
- Division of Hematology-Oncology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan.
- Division of Hematology-Oncology, Department of Internal Medicine, Chiayi Chang Gung Memorial Hospital, Chiayi, Taiwan.
- Division of Hematology-Oncology, Department of Internal Medicine, Linkou Chang Gung Memorial Hospital, No. 5, Fu-Hsing Str., Guishan Dist., Taoyuan City, Taiwan 333423, Republic of China.
ORCID-Profile: Pei-Hung Chang, Yu-Li Su, Jason Chia-Hsun Hsieh, Hung-Chih Hsu
Förderung
- Taiwan Association of Cancer Research
Zitieren
APA
Chang, P. H., Huang, W. K., Su, Y. L., Kuan, F. C., Hsieh, J. C., & Hsu, H. C. (2026). Trifluridine/tipiracil and survival in mismatch repair-deficient metastatic colorectal cancer. Therapeutic Advances in Medical Oncology, 18. https://doi.org/10.1177/17588359261458757
Vancouver
Chang PH, Huang WK, Su YL, Kuan FC, Hsieh JC, Hsu HC. Trifluridine/tipiracil and survival in mismatch repair-deficient metastatic colorectal cancer. Therapeutic Advances in Medical Oncology. 2026;18. doi:10.1177/17588359261458757
BibTeX
@article{Chang2026,
author = {Chang, Pei-Hung and Huang, Wen-Kuan and Su, Yu-Li and Kuan, Feng-Che and Hsieh, Jason Chia-Hsun and Hsu, Hung-Chih},
title = {Trifluridine/tipiracil and survival in mismatch repair-deficient metastatic colorectal cancer},
journal = {Therapeutic Advances in Medical Oncology},
year = {2026},
volume = {18},
doi = {10.1177/17588359261458757}
}
EUVIMED